Background: Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese population. Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-tumor activity. The present data regarding first-line treatment with single agent gefitinib against non-small-cell lung cancer (NSCLC) in Chinese population are not sufficient.

Purpose: To assess the efficacy and toxicity of gefitinib in Chinese patients with advanced non-small-cell lung cancer (NSCLC), a study of single agent treatment with gefitinib in Chinese patients was conducted.

Methods: 45 patients with advanced NSCLC were treated with gefitinib (250 mg daily) until the disease progression or intolerable toxicity.

Results: Among the 45 patients, 15 patients achieved partial response (PR), 17 patients experienced stable disease (SD), and 13 patients developed progression disease (PD). None of the patients achieved complete response (CR). The tumor response rate and disease control rate was 33% and 71.1%, respectively. Symptom remission rate was 72.5%, and median remission time was 8 days. Median overall survival and median progression-free survival was 15.3 months and 6.0 months, respectively. The main induced toxicities by gefitinib were skin rash and diarrhea (53.3% and 33.3%, respectively). The minor induced toxicities included dehydration and pruritus of skin (26.7% and 22.2%, respectively). In addition, hepatic toxicity and oral ulceration occurred in few patients (6.7% and 4.4%, respectively).

Conclusions: Single agent treatment with gefitinib is effective and well tolerated in Chinese patients with advanced NSCLC.
In 2006, Niho et al. reported response rate of 30%, median survival time (MST) of 13.9 months and 1-year survival rate of 55% in advanced NSCLC after first-line single agent treatment with gefitinib[6]. Some other groups also reported that first-line single agent treatment with gefitinib may have better effect in patients with advanced NSCLC than standard first-line chemotherapy [7-10]. Gefitinib showed clinical benefits for EGFR mutation NSCLC patients with extremely poor performance status (PS)[11,12]. The large randomized trial (IPASS research) which compared gefitinib with carboplatin/paclitaxel in patients with advanced NSCLC demonstrated superiority of gefitinib relative to carboplatin/paclitaxel in terms of PFS, ORR, tolerability, and QOL improvement rates. However, the overall survival (OS) and disease-related symptom improvement rates were similar [13]. In 2009, Kim et al. demonstrated that compared to pre-gefitinib eras, the survival of advanced NSCLC patients was significantly improved in post-gefitinib eras in Korea [14].

However, the present data regarding first-line treatment with single agent gefitinib against NSCLC in Chinese population are not sufficient. Here, we conducted a study of single agent treatment with gefitinib in 45 patients with advanced NSCLC in order to assess its efficacy and toxicity in Chinese patients.

Materials and methods

Patients
45 patients with histologically or cytologically confirmed stage IIIIB or IV NSCLC received gefitinib as first-line treatment between July 2006 and Oct 2008 at the First Affiliated Hospital of Nanjing Medical University. All of these patients were treated initially and had at least one measurable focus according to standard Response Evaluation Criteria in Solid Tumors (RECIST) [15]. These 45 patients consisted of 19 males and 26 females with median age around 61.8 years (range: 30-78). 17 patients had smoking history. In terms of tumor histologic types, the patients included 26 adenocarcinomas, 4 bronchioloalveolar carcinomas, 10 squamous cell carcinomas and 5 adenosquamous carcinomas. According to American Joint Committee on Cancer (AJCC) staging manual, 14 patients were in stage IIIIB and 31 patients in stage IV. The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) value was less than 2 in 32 patients, and 3 - 4 in 13 patients (Table 1). All patients provided written informed consent before enrollment. This protocol was approved by the Institutional Review Boards of the participating centers.

Therapy
Gefitinib (AstraZeneca Company) was administered orally 250 mg daily, 28 days as a cycle. The treatment was continued until disease progression or intolerable toxicity.

Table 1 Clinical material and efficacy of the 45 patients

| Characters | NO. | CR, n (%) | PR, n (%) | SD, n (%) | PD, n (%) |
|-----------|-----|-----------|-----------|-----------|-----------|
| Gender    |     |           |           |           |           |
| Male      | 19  | 0         | 15.8(3)   | 36.8(7)   | 47.4(9)   |
| Female    | 26  | 0         | 46.1(12)  | 38.5(10)  | 15.4(4)   |
| Age(year) |     |           |           |           |           |
| < 70      | 35  | 0         | 34.3(12)  | 37.1(13)  | 28.6(10)  |
| ≥70       | 10  | 0         | 30.0(3)   | 40.0(4)   | 30.0(3)   |
| Smoking status |     |           |           |           |           |
| Smokers   | 17  | 0         | 17.6(3)   | 41.2(7)   | 41.2(7)   |
| Non-smokers | 28  | 0         | 42.9(12)  | 35.7(10)  | 21.4(6)   |
| Tumor histology |     |           |           |           |           |
| Adeno.    | 26  | 0         | 38.5(10)  | 42.3(11)  | 19.2(5)   |
| BAC       | 4   | 0         | 75.0(3)   | 25.0(1)   | 0.0(0)    |
| Squamous  | 10  | 0         | 10.0(1)   | 30.0(3)   | 60.0(6)   |
| Adenosquamous | 5   | 0         | 20.0(1)   | 40.0(2)   | 40.0(2)   |
| Stage     |     |           |           |           |           |
| IIIB      | 14  | 0         | 28.6(4)   | 50.0(7)   | 21.4(3)   |
| IV        | 31  | 0         | 35.4(11)  | 32.3(10)  | 32.3(10)  |
| Brain metastasis | 4   | 0         | 75.0(3)   | 25.0(1)   | 0.0(0)    |
| PS value  |     |           |           |           |           |
| ≤2        | 32  | 0         | 37.5(12)  | 37.5(12)  | 25.0(8)   |
| 3~4       | 13  | 0         | 23.0(3)   | 38.5(5)   | 38.5(5)   |

Observation index
We conducted a thorough physical examination on each patient to acquaint with the health status (PS method). Blood routine, hepatic and renal function, electrocardiogram, PET/CT or CT were examined. These indexes were reexamined regularly during the trial, and the image examination was performed after the first one cycle. After that, the image examination was conducted once two cycles. The follow-up of patients by telephone or outpatient service for 1 year was performed.

Evaluative standards
Tumor response was assessed as complete response (CR), partial response (PR), stable disease (SD), or progression disease (PD) in accordance with the standard of RECIST [15]. A CR was defined as the complete disappearance of all clinically detectable tumors for at least 4 weeks. A PR was defined as an at least 30% decrease in the sum of the longest diameters of the target lesions for more than 4 weeks without new area of malignant disease. PD indicated an at least 20% increase in the sum of the longest diameter of the target lesions or a new malignant lesion. Stable disease was defined as insufficient shrinkage to qualify for PR and insufficient increase to qualify for PD. An objective response rate
indicated the proportion of patients achieved CR and PR, while a disease control rate (DCR) indicated the proportion of patients achieved CR, PR and SD. Progression-free survival (PFS) was measured from Day 1 of treatment until the first objective or clinical sign of disease progression. Overall survival (OS) was measured from Day 1 of treatment until the date of death. The alteration of patients’ symptoms including appetite, fatigue, cough, dyspnea, hemoptysis and pain referencing to Lung Cancer Symptom Scale (LCSS) [16] was observed. Symptomatic remission was considered if the score over 25 points. Symptom remission time means the span from initial administration to symptom remission. Adverse effects including 5 degrees (0-IV) were evaluated following the standard enacted by the World Health Organization in 1981.

Statistical considerations
The data was analyzed by SPSS11.5. Intergroup comparison was conducted by X2 checking. Survival analyses were performed by Kaplan-Meier method. Survival deviation was calculated by Log-Rank test. All P-values were considered significant if \( P \leq 0.05 \).

Results
Clinical efficacy
All of these patients were eligible. None of the patients achieved CR. 15 patients (33.3%) achieved PR and 17 patients (37.8%) had stable disease (SD). 13 patients (28.9%) developed progressive disease (PD). ORR and DCR was 33.3% and 71.1% respectively. Subset analysis according to basic traits of the patients was shown in Table 1. Table 2 showed that the efficacy of gefitinib therapy correlated with gender, tumor histology (\( P < 0.05 \)). However, other factors such as age, smoking status, disease stage, and ECOG-PS didn’t correlate with the efficacy of gefitinib therapy.

It is notable that there were 4 patients with brain metastasis in this trial, including 3 cases of PR and 1 case of SD. Brain metastatic focuses disappeared in 2 patients of PR, and their primary tumor reduced. One of them expressed headache palliative at the day 1. The primary and metastatic tumors of one patient reduced two weeks later.

Remission of symptoms
In this trial, except 5 patients whose PS = 0, 29 of the other 40 patients (72.5%) achieved palliative symptoms such as fatigue, cough, pain, etc. Remission time arranged from 1 to 14 days, median remission time was 8 days.

Overall survival
MST of the 45 patients was 15.3 months by Oct 15, 2008, (95% CI 11.22-19.38). OS arrange from 7.4 to 23 months, and the patient who had the longest OS was still alive at the most recent follow-up. The 1-year survival rate was 50%. The Kaplan-Meier survival curve was showed in Figure 1. The MST of patients with adenocarcinoma and non-adenocarcinoma was 17.1 months (95%CI 14.79-19.41) and 11.2 months (95%CI 8.67-13.73), respectively. The MST of patients with adenocarcinoma was remarkably longer than that of non-adenocarcinoma (\( P = 0.0149 \)) (Figure 2). Other factors such as gender, smoking status, etc., had no obvious effects on survival (Smokers indicated current or former smokers, and non-smokers was defined as persons who had never smoked.).

| Table 2 Gradational analysis of ORR and DCR |
|-------------------------------------------|
| Characters                  | ORR(%) | P value | DCR(%) | P value |
|-------------------------------|--------|---------|--------|---------|
| Gender                       |        |         |        |         |
| Male                          | 13.3   | 0.033   | 52.6   | 0.019   |
| Female                       | 40.0   | 84.6    |        |         |
| Age(year)                     |        |         |        |         |
| < 70                          | 34.3   | 1.000   | 71.4   | 1.000   |
| ≥70                           | 30.0   | 70.0    |        |         |
| Smoking status                |        |         |        |         |
| Smokers                       | 17.6   | 0.082   | 58.8   | 0.281   |
| Nonsmokers                    | 42.9   | 78.6    |        |         |
| Tumor histology               |        |         |        |         |
| Adeno. And BAC                | 43.3   | 0.044   | 83.3   | 0.027   |
| Non-adeno.                    | 13.3   | 46.7    |        |         |
| Stage                         |        |         |        |         |
| IIIb                          | 28.6   | 0.909   | 78.6   | 0.699   |
| IV                            | 35.5   | 67.7    |        |         |
| PS value                      |        |         |        |         |
| ≤2                            | 37.5   | 0.561   | 75.5   | 0.589   |
| 3–4                           | 23.1   | 61.5    |        |         |

Figure 1 Kaplan-Meier curve of OS for all patients. The MST is 15.3 months. 1 year survival rate is 50%.
Progression-free survival time
The median PFS was 6.0 months, (95% CI 4.36-7.64). Kaplan-Meier curve of PFS was showed in Figure 3.

Toxicity and adverse effects
As shown in Table 3, the most common toxicities of gefitinib treatment were rash (53.3%) and diarrhea (33%). In addition, 26.7% and 22.2% of the patients showed dehydration and pruritus of skin. 6.7% of the patients showed Grade 2 or 3 hepatic toxicity. 4.4% of the patients (2 persons) showed oral ulcer. No patients developed interstitial lung disease (ILD). Most of the toxicity was grade 1 to 2, and remitted after treatment. Grade 3 rash of one patient was remitted by reducing the dose of gefitinib. The relationship between rash and OS is showed in Figure 4.

Discussion
Because of high morbidity and mortality, investigators pay more attentions to the therapy of lung cancer in recent years. Platinum-based combination chemotherapy has been the standard first-line therapy for advanced NSCLC. However, it brings about severe adverse effects such as vomiting, renal toxicity, cytopenia, etc. Recently, molecular-targeted agents have been introduced in the treatment of NSCLC. Gefitinib, a tyrosine kinase inhibitor of EGFR, has been allowed to treat NSCLC clinically. The second-line treatment with gefitinib has response rate, survival benefit and safety not inferior to chemotherapy. Two trials in patients who previously failed platinum-based chemotherapy, IDEAL-1 and 2, revealed a favorable ORR (12-18%), a DCR of 50%, and good tolerability of gefitinib treatment [2,3]. Gefitinib have been suggested to have better efficacy in patients of females or non-smokers, patients with adenocarcinoma (particularly with bronchioloalveolar carcinoma), patients with previous immune/endocrine therapy, and patients with a PS of 0 or 1 [2]. A trial about the treatment of NSCLC patients from Asia with gefitinib resulted in an ORR more than 25% and a DCR more than 60% [17]. Recently, Lee et al. [5] demonstrated that, as second-line therapy, gefitinib has superior PFS, better tolerability,
and similar QOL improvement rates compared to docetaxel.

Nowadays, more and more clinical investigations have been carried out to evaluate the efficacy of gefitinib as first-line treatment of advanced NSCLC. Niho et al. [6] reported a response rate of 27\% with gefitinib treatment in 40 patients with advanced NSCLC. Yang et al. [18] from Taiwan reported that first-line treatment with gefitinib in 196 patients with NSCLC achieved an ORR of 42\%, a DCR of 61\%, and a 1-year survival rate of 47.5\%.

A large phase III trial IPASS, which was designed to compare gefitinib as first-line treatment of NSCLC patients with standard chemotherapy, demonstrated superiority of gefitinib in terms of 12-month rates of PFS (24.9\% vs. 6.7\%, P < 0.05), ORR (43.0\% vs. 32.2\%, P = 0.0001), and tolerability profile compared with carboplatin plus paclitaxel. Recently, Maemondo et al. [9] reported the gefitinib group had a significantly longer median PFS (10.8 months vs. 5.4 months; P < 0.001), as well as a higher response rate (73.7\% vs. 30.7\%, P < 0.001) than the standard chemotherapy group. A study conducted in Japan also showed a longer PFS in gefitinib group than the cisplatin plus docetaxel group (9.2 months vs. 6.3 months, P < 0.0001) [10]. In our study of first-line treatment with gefitinib in Chinese patients with advanced NSCLC, we obtained an ORR of 33.3\%, a DCR of 71.1\%, a median PFS of 6.0 months, and a median OS of 15.3 months. These results were compatible with the reports aforementioned.

The IPASS study suggested that gefitinib would be efficacious in first-line treatment of locally advanced or metastatic NSCLC patients with adenocarcinoma who have never or seldom smoked [13]. Consistent with this result, we found that females and patients with adenocarcinoma (including bronchioloalveolar carcinoma) were more sensitive to gefitinib. Although the response rate of gefitinib in non-smokers seemed higher than that in smokers, the result had no statistical significance due to the small sample size. The OS of patients with adenocarcinoma was longer than that of patients with non-adenocarcinoma (17.1 months vs. 11.2 months, P = 0.0149). However, other factors such as gender and smoking status have no obvious correlation to OS. In addition, we found that the OS of patients with rash was longer than that of patients without rash, and a longer OS was coupled with greater rash. Because there were few cases with grade 2 or more serious rash, this result needs to be verified further. Moreover, our study showed favorable efficacy of gefitinib in patients with brain metastasis.

Gefitinib is well tolerated in advanced NSCLC. The common adverse effects of gefitinib were skin rash, diarrhea, anorexia, elevated aminotransferase level, and interstitial lung disease, etc [9-11,19]. Similarly, mild toxicities including skin rash (53.3\%), diarrhea (33\%), Grade 2 or 3 hepatic toxicity (6.7\%), and oral ulcer (4.4\%) were observed in our study. No patients developed ILD. Since the tolerance of gefitinib in NSCLC is better than chemotherapy, and gefitinib could provide clinical benefits for patients with extremely poor PS [11,12], it may be a better choice to treat patients who can’t tolerate chemotherapy compared to best supportive care (BSC).

It has been recently reported that the sensitivity and survival benefit of gefitinib treatment was higher in NSCLC patients with EGFR mutations than the patients without EGFR mutations [20-22]. Chinese patients of lung cancer have a higher frequency of EGFR mutations than American patients. As a result, Chinese patients were much more sensitive to gefitinib than Americans [23]. Besides mutations, gene copy number and polymorphism of EGFR were also related to the responsiveness of gefitinib in advanced NSCLC [24,25]. EGFR mutations of NSCLC patients can be detected using plasma and pleural effusion samples, which provides a noninvasive method to predict the efficacy of gefitinib in advanced NSCLC [26]. Detecting the mutations of EGFR plays an important role in guiding the first-line treatment with gefitinib in patients with advanced NSCLC. Besides EGFR mutations, the favorable PFS after gefitinib treatment was also associated with high levels of serum surfactant protein D (SP-D) [27]. In future studies, we will investigate the molecules which affect and (or) can be used to predict the efficacy of gefitinib in NSCLC.

Conclusions

Single agent treatment with gefitinib is effective in patients with advanced NSCLC, and well tolerated in Chinese patients. Gefitinib could be used as first-line treatment for specific subgroups of NSCLC such as females, non-smokers, and patients with adenocarcinoma.

Abbreviations

NSCLC: non-small-cell lung cancer; TK: tyrosine kinase; EGFR: epidermal growth factor receptor; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; PFS: progression-free survival; ORR: objective response rate; QOL: quality of life; PS: performance status; ECOG-PS: Eastern Cooperative Oncology Group performance status; DCR: disease control rate; OS: overall survival; REGIST: Response Evaluation Criteria In Solid Tumors; LCSS: Lung Cancer Symptom Scale; MST: median survival time; ILD: interstitial lung disease; BSC: best supportive care; TTP: time to progression; SP-D: serum surfactant protein D.

Acknowledgements

This work was supported by grants from the Jiangsu Provincial Natural Science Foundation (NO. BK2008477), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry 2009 (IA09), and the open project program of the Health Bureau of Jiangsu province (XK18 200904).
Author details
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road: #300, Nanjing 210029, P.R. China. 2Department of Chest Surgery, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road: #300, Nanjing 210029, P.R. China. 3Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Jiangsiaojian, #121, Xiaoguan District, Nanjing 210011, P.R. China.

Authors’ contributions
YQs contributed to conception and design, and gave final approval of the version to be published. ZYW contributed to conception and design. YMY acquired the data and revised the manuscript critically for important intellectual content. YTG acquired the data and drafted the manuscript. YFS acquired the data. XLH and WL contributed to statistical analysis. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 21 May 2010 Accepted: 15 September 2010
Published: 15 September 2010

References
1. Wakeding AE, Barker AJ, Davies DH, Brown DS, Green LR, Cardillo SA, Woodburn JR: Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996, 38:67-73.
2. Fukushima M, Yano S, Giacccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Yanasteenkistie K, Kudoh S, Risch D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, MacLeod A, Feyerolleova A, Dong RP, Baselga J: Multi-institutional randomized randomized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003, 21:2327-2246.
3. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spinnonditis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003, 290:2449-2518.
4. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16:1307-1314.
5. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F, Xu GC, Zhang L, Guan ZZ: Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP). Zhonghua Zhong Liu Za Zhi 2009, 31:148-151.
6. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y: First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study. J Clin Oncol 2006, 24:64-69.
7. D’Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Biilh M, Mayer M, Ribi K, Lerch S, Hubendurk L, Bittich DC. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008, 19:739-747.
8. Ebi N, Somba H, Tukunaga SJ, Takayama K, Wataya H, Kuriaki T, Yamamoto H, Akamine S, Okamoto I, Nakanishi Y: Phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1166-1171.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kioniota J, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
10. Lee YJ, Kim HT, Han JY, Yoon T, Lee GK, Kim HY, Sung JH, Lee JS. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010, 5:361-368.
11. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Monta S, Hagiwara K, North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation without indication for chemotherapy. J Clin Oncol 2009, 27:1550-1554.
12. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpawerawong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewvaskalyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuda M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
13. Kim HS, Park K, Jun HJ, Yi SY, Lee JH, Park JS, Park YH, Kim S, Lee S, Ahn MJ: Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009, 76:239-246.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Linch D, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther S, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
15. Holen PJ, Gralla RJ, Kris MG, Potanovich LM: Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993, 29:Suppl 1:551S-558.
16. Shen Lu, Ziming U: Targeted therapy of lung cancer-data from Asia. China oncolgy 2007, 178-13.
17. Sharon CH, Shih JY, Chen KC, Yu C, Yang HY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC: Survival outcome and predictors of gefitinib antitumor activity in Asian Eastern chemonaive patients with advanced non-small cell lung cancer. Cancer 2006, 107:1873-1882.
18. Moiseenko VM, Protosenko SA, Semenov II, Moiseenko FY, Levchenko EV, Barchuk AS, Matsko DE, Ivan'tsovo AO, Ivleva AG, Mitsukhina VN, Togo AV, Iminavit EN: Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study). Vopr Onkol 2010, 56:20-23.
19. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Setteman J, Iafate JR, Engelman J, Haber DA, Johnson BE, Lynch TJ: First-line Gefitinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations. J Clin Oncol 2008, 26:2442-2449.
20. Sugio K, Uramoto H, Onitsuka T, Mizukami M, Ichile Y, Sugaya M, Yasuda M, Takeymo Y, Oyama T, Harogangi T, Yamasato K: Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009, 64:314-318.
21. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INSTITUTE trial. J Clin Oncol 2010, 28:744-752.
22. Xu XL, Li LY, Zhang XT, Wang NZ, Feng RE, Liu QC, Zhou HS, Guo QY: Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non-Small Cell Lung Cancer. J Cancer Res Clin Oncol 2005, 131:249-249.
27. Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S: Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010.

doi:10.1186/1756-9966-29-126
Cite this article as: Yin et al.: First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. Journal of Experimental & Clinical Cancer Research 2010 29:126.